NeuroSense Therapeutics Ltd. SEC filings NRSNW
NeuroSense Therapeutics Ltd. has 314 filings in SEC EDGAR's recent list, going back to Aug 9, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | Mar 31, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 7, 2025 | Dec 31, 2024 |
| 20-F | Annual report (foreign issuer) | Apr 4, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 22, 2023 | Dec 31, 2022 |
| 20-F | Annual report (foreign issuer) | Apr 14, 2022 | Dec 31, 2021 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRSN (Nasdaq), NRSNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Herzliya, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1875091
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.